{"id":"W4296530176","doi":"10.1016/s2152-2650(22)01456-2","title":"MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Anemia; Phases of clinical research; Fibrosis; Extramedullary hematopoiesis; Surgery; Bone marrow; Clinical trial; Haematopoiesis; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00281727,0.001162834,0.001882212,0.0004214358,0.0009630996,0.000243249,0.002018888,0.0002644894,0.0005611238],"category_scores_gemma":[0.001863327,0.0006869888,0.0002037592,0.001835874,0.0007782704,0.0005341234,0.002823974,0.001319905,0.0002249981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002049163,"about_ca_system_score_gemma":0.004367315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001860233,"about_ca_topic_score_gemma":0.001197379,"domain_scores_codex":[0.9872471,0.00273194,0.002031403,0.002871346,0.00326745,0.001850747],"domain_scores_gemma":[0.9874219,0.005441955,0.0006304255,0.004484398,0.0005084155,0.001512922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3805119,0.006233795,0.5894485,0.00004169438,0.0006506159,0.004731943,0.0006957143,0.00002454472,0.00002187966,0.000006356866,0.003247433,0.01438562],"study_design_scores_gemma":[0.06947618,0.07887579,0.8432909,0.0005303151,0.0005193849,0.0001848576,0.003304516,0.0003068265,0.00005726673,0.000007599182,0.002640174,0.0008062572],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870881,0.00007368682,0.000006587828,0.001639254,0.0002621241,0.007661905,0.002716121,0.0002456151,0.0003065729],"genre_scores_gemma":[0.9896997,0.00001004964,0.002190204,0.001339045,0.0005465692,0.001367805,0.003433396,0.0002984722,0.001114737],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3110358,"threshold_uncertainty_score":0.9995582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05084599366323148,"score_gpt":0.3320740202494757,"score_spread":0.2812280265862442,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}